Key Points The growth hormone (GH)insulin-like growth factor (IGF) axis consists of central neuro-anatomical, regulatory and genetic systems, and the peripheral intracellular GH signalling pathway The introduction of recombinant human GH (rhGH) in 1985 ended the phase of pituitary-derived human growth hormone (hGH) and its associated limitations and risks, opening the possibility of widespread clinical use GH deficiency (GHD) is a syndrome with many different causes and is associated with alterations in growth, body composition and metabolism In some non-GHD short stature disorders, rhGH has been proved effective and is used as a surrogate for the currently unknown, pathophysiologically appropriate treatment Risks of hGH therapy might relate to its direct effects on growth, its anti-insulin action and its cell-proliferating activity
In terms of roles, my focus is in the R&D, the formulations and the ingredients
GLP-1 RA, mainly liraglutide, might represent interesting molecules to tackle the weight excess that is associated with metabolic abnormalities, hyperandrogenism, infertility, and menstrual alterations in PCOS women
HIMIYER 10 Star Ingredients Detailed Benefits